Dinesh Kamath's news 'Glenmark Pharmaceuticals takes a Green Step' that was published in Newsband

Glenmark Pharmaceuticals takes a Green Step

Installs rooftop solar plant at its R&D Centre in Mahape, Navi Mumbai

By Dinesh Kamath

MIDC: Underlying its commitment to environmental sustainability, Glenmark Pharmaceuticals Limited announced the installation of a 100 kWp rooftop solar plant at its R&D Centre in Mahape, Navi Mumbai. This is a first-of its kind large-scale green initiative by a company in this industrial area. Spread over 10,000 sq. ft., the rooftop plant has the capacity to generate up to 400 units of power each day.

For this project, Glenmark has partnered with Fourth Partner Energy, a full services Renewable Energy Services Company (“RESCO”) focused on captive solar power. The project is estimated to achieve close to 125 tonnes of carbon dioxide equivalents reduction every year. This is equivalent to the power generated using 6,900 mature trees; implying significant environmental protection. The carbon dioxide abatement compared to coal fired thermal power is estimated to be close to 77 tonnes per annum.

“We are delighted at the successful installation of the rooftop solar plant our Mahape R&D Center. The project is a big step forward in reducing our environmental footprint. Over the years, Glenmark facilities have taken a number of measures in conserving natural resources, preventing pollution and minimizing environmental impact”; said Cheryl Pinto – Director Corporate Affairs, Glenmark Pharmaceuticals Limited. In addition to the solar power plant, Glenmark has undertaken several initiatives across the organization towards energy saving. Glenmark has enhanced existing systems and adopted newer technologies towards recycling and reusing resources. Through its efforts, Glenmark has been able to save about 6730 megawatt-hours of electricity across its plants and R&D Centers in the Financial Year 2014-15.

About Glenmark R&D Center in Mahape

Glenmark’s R&D Center at Mahape, Navi Mumbai, India is engaged in the discovery of new chemical entities aimed at meeting the unmet medical needs. Spread over 1,25,000 sq. ft. the R&D Centre has end-to-end capabilities for discovery and development of New Chemical Entities (NCEs) from target selection to clinical development. The research facility is equipped with modern infrastructure required to carry out research activities like medicinal chemistry, process & analytical chemistry, in vitro & in vivo studies and project management.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (GPL) is a research‐driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2015). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].

The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 16 manufacturing facilities in five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western Europe markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.